Julie Vose, MD, discusses the exciting developments across lymphomas.
Julie M. Vose, MD, MBA
Advertisement
Articles by Julie M. Vose, MD, MBA
Julie M. Vose, MD, MBA, discusses the importance of conducting genetic testing on all patients with diffuse large B-cell lymphoma to better understand their disease and treat the disease properly.
Julie M. Vose, MD, MBA, discusses resistance to BTK inhibitors in patients with non-Hodgkin lymphoma.
Julie M. Vose, MD, MBA, Chief in the Division of Oncology/Hematology at the University of Nebraska Medical Center, discusses strategies for overcoming resistance in lymphoma during the 2018 Pan Pacific Lymphoma Conference.
Advertisement
Latest Updated Articles
Exploring Novel Agents to Target Pathways in LymphomaPublished: August 9th 2018 | Updated:
Overcoming BTK Inhibitor Resistance in NHLPublished: October 19th 2018 | Updated:
Rationale for Genetic Testing in Patients With DLBCLPublished: November 19th 2018 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
